1BP-LSD

1BP-LSD is a novel lysergamide research chemical that emerged on the European market in 2023 following the scheduling of 1V-LSD under Germany's New Psychoactive Substances Act (NpSG) in July 2022. Like its predecessors 1P-LSD, 1cP-LSD, and 1V-LSD, it is classified as an acylated prodrug of LSD-25 — an initially inactive precursor that is converted in vivo to the parent compound lysergic acid diethylamide through enzymatic hydrolysis. As of 2026, 1BP-LSD is not scheduled under the German Narcotics Act (BtMG) or NpSG and is sold as a research chemical not intended for human consumption.

Chemistry

1BP-LSD belongs to the family of 1-acylated lysergamides: LSD-25 derivatives in which an acyl group is attached to the nitrogen atom at the 1-position of the indole ring system. Its approximate molecular mass is ~407 g/mol, placing it above both LSD-25 (~323 g/mol) and the closely named 1B-LSD (1-butanoyl-LSD, ~393 g/mol). Despite commercial sources occasionally describing the acyl substituent simply as a "butanoyl group", the molecular mass difference of approximately 14 Da compared to 1B-LSD indicates a structurally distinct acyl moiety — likely a branched or extended five-carbon acyl chain rather than the straight four-carbon butanoyl group of 1B-LSD.

The compound is commercially available as blotters (typically 100 µg and 175 µg) and pellets (10 µg for microdosing, 250 µg for experienced users). Like all lysergamide prodrugs, 1BP-LSD is sensitive to degradation by heat, UV radiation, moisture, and oxidation. Storage in opaque, airtight packaging at room temperature or below is essential for preserving potency.

Pharmacology

1BP-LSD functions as a prodrug of LSD-25. Upon ingestion, the acyl substituent at position 1 is cleaved by esterases and hepatic enzymes, releasing free LSD-25 into the bloodstream. This metabolic activation step accounts for the characteristically delayed onset of 45–90 minutes compared to LSD-25 itself (which can take effect within 20–30 minutes when absorbed sublingually).

Once converted, the pharmacological profile is indistinguishable from LSD-25. The active metabolite is a potent partial agonist at serotonin 5-HT₂A receptors — the primary molecular target responsible for the psychedelic state — as well as 5-HT₂B, 5-HT₂C, 5-HT₁A, and various dopamine receptors (D₁, D₂). Downstream effects include activation of the intracellular signalling cascade involving β-arrestin-2, which is believed to mediate the prolonged subjective effects and unique phenomenology of lysergamides.

Due to its higher molecular mass relative to LSD-25, 1BP-LSD delivers fewer molecules of active LSD per microgram of substance. In practical terms it is approximately 15–20 % less potent per unit weight than LSD-25, and roughly comparable to other high-mass prodrugs such as 1V-LSD. 150 µg of 1BP-LSD is commonly reported to produce effects comparable to 100–125 µg of LSD-25, although individual variation in metabolism can shift this ratio.

Complete cross-tolerance develops with all serotonergic psychedelics acting at 5-HT₂A receptors, including psilocybin, mescaline, DMT, and all other LSD prodrugs. Tolerance dissipates over approximately 10–14 days.

Effects

The subjective effects of 1BP-LSD mirror those of LSD-25 and include:

• Visual effects: enhanced colour saturation, geometric patterning, trailing, tracers, fractal structures, and, at higher doses, complex closed-eye imagery and visual "breathing" of surfaces
• Cognitive effects: intensified introspection, conceptual thinking, altered time perception, synesthetic crossover between senses, and thought acceleration
• Emotional effects: euphoria, a sense of connectedness or unity, emotional lability, and occasionally anxiety or confusion — particularly at high doses or in unfavourable settings
• Physical effects: pupil dilation (mydriasis), increased heart rate, mild nausea during the comeup, jaw clenching, body-temperature fluctuations, and a moderate "body load" that is frequently described as slightly more pronounced than with 1FE-LSD

The comeup is typically described as gentle and gradual owing to the slow prodrug conversion, reaching full peak effects 2–3 hours after ingestion. Users frequently characterise the 1BP-LSD experience as warm, creative, and mildly euphoric with strong visual enhancement. The total duration at a common dose is 8–12 hours, with residual aftereffects (mood shift, mild visual enhancement, altered sleep) lasting up to 24 hours.

Microdosing (10–20 µg, sub-perceptual) is a popular use case. At these doses no overt psychedelic effects occur; users report enhanced creativity, improved mood, and heightened focus. Microdose effects typically persist for 6–8 hours.

Harm Reduction

• Unpredictable individual response: genetic variation in esterase activity can accelerate or delay prodrug conversion, leading to atypical timing or intensity. Never assume a missed onset means the substance is inactive.
• Serotonin syndrome risk: combining 1BP-LSD with serotonergic drugs (SSRIs, SNRIs, MAOIs, tramadol, lithium) can cause additive or synergistic serotonergic toxicity. The interaction with lithium is particularly dangerous and may trigger seizures.
• Cardiovascular load: LSD-25 modestly increases heart rate and blood pressure. Individuals with pre-existing cardiac conditions or uncontrolled hypertension should exercise caution.
• Psychological vulnerability: psychedelics can precipitate or exacerbate psychotic episodes in individuals with a personal or family history of schizophrenia spectrum disorders or bipolar disorder. Screening for these conditions is strongly advisable before use.
• HPPD (Hallucinogen-Persisting Perception Disorder): a small fraction of psychedelic users develop persistent visual disturbances after use. Risk factors include high doses, frequent use, pre-existing anxiety, and cannabis co-use. The condition is usually mild and self-resolving but can be distressing.
• Reagent testing: Ehrlich's reagent produces a purple/violet reaction with indole-containing lysergamides, confirming the presence of an LSD-type compound. Hofmann reagent provides a secondary confirmation. These tests cannot distinguish between individual LSD prodrugs but can rule out dangerous substitutes like NBOMes.

Related Compounds

• LSD-25 (lysergic acid diethylamide) — the parent compound to which 1BP-LSD is converted in vivo
• 1B-LSD (1-butanoyl-LSD) — a structurally related but distinct prodrug with a lower molecular mass (~393 g/mol); scheduled under the German NpSG
• 1P-LSD (1-propionyl-LSD) — the first widely available LSD prodrug; scheduled in Germany since 2019
• 1cP-LSD (1-cyclopropionyl-LSD) — scheduled in Germany since 2022
• 1V-LSD (1-valeroyl-LSD) — scheduled under the German NpSG since July 2022
• 1D-LSD — a currently legal lysergamide prodrug sold alongside 1BP-LSD
• 1S-LSD — another legal lysergamide derivative
• 1FE-LSD (1-(2-fluoroethanoyl)-LSD) — a newer prodrug (~395 g/mol) considered slightly more potent per microgram and characterised by a faster onset and lower body load than 1BP-LSD